Trial Profile
A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix 30 as Monotherapy, or in Combination With OHAs, in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Antihypoglycaemics
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PRESENT
- Sponsors Novo Nordisk
- 01 Mar 2012 New trial record